BloodScan Biotech Inc. is a premier biotechnology company at the forefront of global precision oncology. Founded by a distinguished research team from the University of Michigan, BloodScan has successfully completed a core technology transfer to drive breakthrough innovations in the field of Liquid Biopsy. We are dedicated to providing more accurate, non-invasive, and revolutionary solutions for cancer detection. In-house R&D: World-Leading Microfluidic Technology BloodScan possesses exceptional R&D capabilities. Our flagship product, Labyrinth One - Automatic CTC Enrichment System, is currently the world’s only liquid biopsy system capable of matching the performance of traditional tissue biopsies. Utilizing our proprietary microfluidic technology, we can isolate Circulating Tumor Cells (CTCs) from a single tube of blood with high purity. Its ultra-sensitive detection capabilities even extend to identifying signs of cancer before "Stage 0." The system offers three core advantages: • Stable Isolation of Late-stage CTCs: Precision support for disease monitoring and real-time treatment tracking for advanced cancer patients. • Tissue-Equivalent Performance: Delivers diagnostic accuracy and molecular information integrity comparable to traditional pathological biopsies. • Ultra-sensitive Early Screening: Significantly increases early cancer detection rates, empowering clinicians to make informed, precision-based medical decisions. Marketing and Global Operations BloodScan operates on a dual-track business model of "Technological R&D" and "Strategic Licensing." By collaborating with major medical centers and Laboratory Developed Test (LDT) facilities worldwide, we integrate the Labyrinth One - Automatic CTC(Circulating Tumer Cell) Enrichment System into clinical diagnostics and drug development pipelines. Currently, we are aggressively expanding across the U.S. and Asian markets. While maintaining a deep R&D foundation in the United States, we leverage distribution and co-development models overseas to broaden the horizons of preventive medicine and personalized healthcare. Vision and Future Goals Our vision is to establish CTC detection as the gold standard for next-generation cancer diagnostics. BloodScan will continue to cultivate the precision medicine ecosystem, assisting global healthcare systems in achieving earlier, more accurate, and more personalized cancer care—truly delivering on the promise of "Early Detection, Precision Treatment."

Labyrinth One - Automatic CTC Enrichment System